Serge Timsit

Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage.

AVCare SAS engages in biotechnology research and development. It operates in the development of stroke blood biomarker. The company was founded by Serge Timsit and Jean-Marc Herbert on October 01, 2019 and is headquartered in Brest, France.

Neurotech's founders have many years of experience in the development of innovative (cochlear) implants and implantable recording/stimulation electrodes. Neurotech SA was incorporated in 1996 to design, develop, manufacture and market active implantable medical devices for the treatment of debilitating disorders by neurostimulation. The Company, in the heart of Europe near Brussels, has since acquired significant expertise in applied biomedical technology.